p53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin

Cancer Research

Volumn 61, Issue 8, 2001, Pages 3373-3381

  Huang, S ^a   Liu, L N ^a   Hosoi, H ^a   Dilling, M B ^a   Shikata, T ^a   Houghton, P J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; PROTEIN P21; PROTEIN P53; RAPAMYCIN;

ALLELE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FIBROBLASTS; G1 PHASE; HUMANS; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN KINASES; RHABDOMYOSARCOMA; SIROLIMUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035870281     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. 1-arresting rapamycin receptor complex
2. RAPT1, a mammalian homolog of yeast TOR, interacts with the FKBP/rapamycin complex
3. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs
4. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin
5. Regulation of eIF-4E BP1 phosphorylation by mTOR
6. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycin associated protein
7. Phosphorylation and activation of p70s6k by PDK1
8. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k
9. PHAS-I as a link: Between mitogen-activated protein kinase and translation initiation
10. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function
11. Remarks on the mechanism of ribosome binding to eukaryotic mRNAs
12. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor
13. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells
14. p53 mutations in human cancers
15. p53, the cellular gatekeeper growth and division
16. Cell cycle control and cancer
17. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
18. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
19. WAF1/CIP1 repression in UV induced apoptosis
20. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen
21. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs
22. Wild-type p53 mediates apoptosis by EIA, which is inhibited by E1B
23. p53 is required for radiation-induced apoptosis in mouse thymocytes
24. p53 in signaling checkpoint arrest or apoptosis
25. The cellular response to p53: The decision between life and death
26. Effects of p53 mutation on apoptosis in mouse intestinal and human colonic adenomas
27. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53
28. 1 checkpoint control
29. 1 arrest and apoptosis
30. WAF1, a potential mediator of p53 tumor suppression
31. 1 cyclin-dependent kinases
32. Principles of CDK regulation
33. The retinoblastoma protein and cell cycle control
34. p21 is a universal inhibitor of cyclin kinases
35. 1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage
36. Waf1/Cip1/sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53
37. Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells
38. Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype
39. KIP1 in inducing cell cycle arrest, apoptosis, and inhibition of tumorigenicity
40. Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells
41. waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin
42. Waf-1 and arrests macrophage cell cycle preventing induction of apoptosis
43. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis
44. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
45. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
46. Studies on the mechanism of resistance to rapamycin in human cancer cells
47. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue
48. 115 in MyoD positively regulates function in murine fibroblasts and human rhabdomyosarcoma cells
49. 1 arrest in mammalian cells
50. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors
51. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma
52. cdc2 kinase activation in T lymphocytes
53. 1-prolongation of NIH3T3 cells
54. 1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability
55. Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin
56. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
57. CCI-779, a new rapamycin analog, has antitumor activity at doses inducing only mild cutaneous effects and mucositis: Early results of an ongoing Phase I study